The advanced glycation end-product Nɛ-(carboxymethyl)lysine level is elevated in cerebrospinal fluid of patients with amyotrophic lateral sclerosis
- 1 November 2004
- journal article
- research article
- Published by Elsevier in Neuroscience Letters
- Vol. 371 (2-3) , 226-229
- https://doi.org/10.1016/j.neulet.2004.08.071
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 DiabetesNew England Journal of Medicine, 2003
- Glycation—a sweet tempter for neuronal deathBrain Research Reviews, 2003
- Biochemistry and molecular cell biology of diabetic complicationsNature, 2001
- Amyotrophic Lateral SclerosisCell, 2001
- El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosisAmyotrophic Lateral Sclerosis, 2000
- Advanced Glycation Endproducts in Neurofilament Conglomeration of Motoneurons in Familial and Sporadic Amyotrophic Lateral SclerosisMolecular Medicine, 1998
- Formation of plasma advanced glycosylation end products (AGEs) has no influence on plasma viscosityDiabetic Medicine, 1997
- Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body diseaseBrain Research, 1996
- The Advanced Glycation End Product, N∊-(Carboxymethyl)lysine, Is a Product of both Lipid Peroxidation and Glycoxidation ReactionsJournal of Biological Chemistry, 1996
- Hydroxyl radical production and autoxidative glycosylation. Glucose autoxidation as the cause of protein damage in the experimental glycation model of diabetes mellitus and ageingBiochemical Journal, 1988